Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers
In an online survey of 1,221 people using psychedelics naturalistically, disclosure to clinicians was low (22% to primary care vs 58% to psychiatric providers), 81% wanted therapist support but only 15% received it, and 23% reported same-day use with potentially interacting psychiatric medications. These findings indicate a substantial disconnect between psychedelic use and clinical care with attendant safety risks, underscoring the need for improved clinician education and policy reforms oriented to harms and benefits.
Authors
- Kevin Boehnke
- Daniel Kruger
- Moss Herberholz
Published
Abstract
Introduction
There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics are criminalized under federal law in the USA, so it is unclear whether use occurs with clinical support. Our objective was to assess whether naturalistic psychedelic use occurs with clinical support, interactions between those using psychedelics and healthcare providers (psychiatrist, therapist, or primary physicians), and use characteristics.
Methods
We conducted an online, anonymous, confidential, cross-sectional survey of adults reporting psychedelic use (N = 1221) through a psychedelics advocacy event and social media between 9/18/2022 and 11/5/2022. We assessed participant disclosure of psychedelic use with their psychiatric care provider (PsyCP) and/or primary care provider (PCP), desire for provider support, access to support, and rate of taking prescribed psychoactive medications alongside psychedelics.
Results
Among participants with such care providers, 22% disclosed psychedelic use to their PCP vs. 58% to their PsyCP. Participants were less confident in PCP vs. PsyCP ability to integrate psychedelics into treatment. Common reasons for nondisclosure included stigma, inadequate provider knowledge, and legal concerns. 23% reported taking psychedelics on the same day as potentially interacting psychiatric medications (e.g., anxiolytics, antidepressants). Despite 81% of participants desiring therapist support during psychedelic experiences, only 15% had received such support.
Discussion
Our results show that psychedelic use is generally disconnected from primary and psychiatric clinical care. This disconnection may result in safety issues, including inadequate screening for contraindicated conditions, lack of support during emergent adverse events, and drug interactions. Enhanced clinical education and orienting drug policy towards known harms and benefits of psychedelics is needed.
Research Summary of 'Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers'
Introduction
Psychedelic research has expanded rapidly in recent years, driven by shifting policy landscapes and interest in alternative treatments for psychiatric conditions. Clinical trials have reported promising results for psychedelic-assisted psychotherapy across disorders such as major depression, treatment-resistant depression, cancer-related anxiety and depression, alcohol and tobacco dependence, and post-traumatic stress disorder; other compounds including MDMA, ayahuasca (DMT), ketamine, and LSD have also yielded therapeutic signals. At the same time, psychedelics remain criminalised under federal law in the United States for most compounds, new local decriminalisation initiatives are emerging, and naturalistic self-administration outside formal clinical settings appears to be increasing. Prior surveys suggest many people use psychedelics for mental health reasons but often do not disclose use to healthcare providers because of stigma, legal concerns, or doubts about provider knowledge, raising safety concerns such as contraindicated conditions and drug interactions. Boehnke and colleagues set out to characterise interactions between people who use psychedelics naturalistically and their healthcare providers. The study aimed to quantify disclosure of psychedelic use to primary care providers (PCPs) and psychiatric care providers (PsyCPs), assess participants’ desire for and access to professional support around psychedelic experiences, identify reasons for nondisclosure, and document concurrent use of prescribed psychoactive medications. The authors hypothesised that disclosure would be more common to PsyCPs than PCPs, while confidence in providers’ ability to integrate psychedelics into care would remain low despite a general desire for therapeutic support.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Boehnke, K. F., Cox, K., Weston, C., Herberholz, M., Glynos, N., Kolbman, N., Fields, C. W., Barron, J., & Kruger, D. J. (2023). Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1224551
References (23)
Papers cited by this study that are also in Blossom
Davis, A. K., Agin-Liebes, G. I., España, M. et al. · Journal of Psychoactive Drugs (2021)
Barnett, B. S., Beaussant, Y., King, K. et al. · Journal of Psychoactive Drugs (2021)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Show all 23 referencesShow fewer
Bogenschutz, M. P., Ross, S., Bhatt, S. R. et al. · JAMA Psychiatry (2022)
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
Jerome, L., Feduccia, A. A., Wang, J. B. et al. · Psychopharmacology (2020)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)
Holze, F., Gasser, P., Müller, F. et al. · Biological Psychiatry (2023)
Glynos, N., Fields, C. W., Barron, J. et al. · Journal of Psychoactive Drugs (2022)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Kruger, D. J., Enghoff, O., Herberholz, M. et al. · Journal of Psychoactive Drugs (2023)
Sarparast, A., Thomas, K., Malcolm, B. et al. · Psychopharmacology (2022)
Malcolm, B., Thomas, K. · Psychopharmacology (2021)
Aday, J. S., Skiles, Z., Eaton, N. et al. · Psychedelic Medicine (2023)
Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.